This is guideline from NICE on a newly recommended treatment for chronic idiopathic constipation.
The medication is Lubiprostone, which works by activating chloride channels in the GI tract, thus increasing intestinal secretions and improving constipation.
It has a different method of action to prucalopride, which NICE released guidance on in 2011. Lubiprostone is more cost-effective than prucalopride.
We can use Lubiprostone in adults who have chronic idiopathic constipation and who meet the following criteria:
- Have tried at least 2 different laxatives from different classes
- For at least 6m
- Have failed to have an adequate response
- Where lifestyle measures have not been effective
- In whom invasive treatment is being considered
It should work within 2 weeks, so patients should be reviewed then and it should be stopped if it has not worked.
Latest posts by Louise Hudman (see all)
- Nice | Who should we be testing for cirrhosis? - October 3, 2016
- Nice | Non-alcoholic fatty liver disease NAFLD - August 26, 2016
- Evolocumab and Alirocumab for treating dyslipidaemia - August 25, 2016